Standard BioTools
LAB
113 hedge funds and large institutions have $355M invested in Standard BioTools in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 29 increasing their positions, 52 reducing their positions, and 34 closing their positions.
33% more call options, than puts
Call options by funds: $2.1M | Put options by funds: $1.57M
32% more capital invested
Capital invested by funds: $269M → $355M (+$85.9M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.78% less ownership
Funds ownership: 79.63% → 76.85% (-2.8%)
18% less funds holding
Funds holding: 138 → 113 (-25)
44% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 52
74% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$12.2M |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$9.82M |
| 3 |
NIM
Needham Investment Management
New York
|
+$4.53M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$2.06M |
| 5 |
State Street
Boston,
Massachusetts
|
+$923K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPA
Cowen Prime Advisors
New York
|
-$4.44M |
| 2 |
SC
Samjo Capital
New York
|
-$3.68M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$3.05M |
| 4 |
Morgan Stanley
New York
|
-$2.91M |
| 5 |
Two Sigma Advisers
New York
|
-$2.59M |
LAB Hedge Fund Activity: Q2 2021 in Review
113 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q2 2021, worth a combined $355M — up 32% from $269M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of LAB and 9 opened new positions — a net loss of 25 holders — while 52 trimmed existing stakes and 29 added.
The largest buyer was Millennium Management, adding an estimated $12.2M. The largest seller was Cowen Prime Advisors, exiting entirely with an estimated $4.44M sold.
- 113 institutional investors held Standard BioTools (LAB) as of Q2 2021, down from 138 in Q1 2021.
- Funds reported $355M of Standard BioTools stock for Q2 2021, up 32% quarter-over-quarter.
- 9 funds opened new Standard BioTools positions in Q2 2021 and 34 closed out, a net change of -25 holders.
- The largest Standard BioTools buyer in Q2 2021 was Millennium Management, an estimated $12.2M added.
- The largest Standard BioTools seller in Q2 2021 was Cowen Prime Advisors, an estimated $4.44M sold.
Based on aggregated 13F filings for Q2 2021.